Intellia Therapeutics, Inc. (NTLA) came out with a quarterly loss of $1.31 per share versus the Zacks Consensus Estimate of a loss of $1.21. This compares to loss of $1.40 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -8.26%. A quarter ago, it was expected that this company would post a loss of $1.35 per share when it actually produced a loss of $1.06, delivering a surprise of 21.48%. Over the last four quarters, the compan ...

Core Insights - Intellia Therapeutics reported positive results from the Phase 2 study of NTLA-2002 for hereditary angioedema, meeting all primary and secondary endpoints, and plans to advance to a pivotal Phase 3 trial with a selected 50 mg dose [1][2][3] - The company is on track to initiate multiple Phase 3 trials for NTLA-2001 and NTLA-3001 by the end of 2024, expanding its clinical pipeline [1][4][5] - Intellia ended Q2 2024 with approximately $940 million in cash, indicating a strong financial position to support ongoing and future clinical trials [1][9] Hereditary Angioedema (HAE) - NTLA-2002 demonstrated significant efficacy with a 98% mean reduction in monthly HAE attack rate and a high percentage of patients remaining attack-free for over 18 months after treatment [3] - The FDA has provided support for the Phase 3 plans following a successful end-of-Phase 2 meeting, with the trial expected to start in the second half of 2024 [2][3] Transthyretin (ATTR) Amyloidosis - NTLA-2001, now known as nexiguran ziclumeran (nex-z), is advancing rapidly in the Phase 3 MAGNITUDE trial for ATTR amyloidosis with cardiomyopathy, with regulatory approvals in over 12 countries [4] - A pivotal Phase 3 trial for hereditary ATTR amyloidosis with polyneuropathy is planned to begin by year-end 2024 [4] Alpha-1 Antitrypsin Deficiency (AATD) - NTLA-3001 is set to initiate a Phase 1/2 study in the second half of 2024, targeting AATD-associated lung disease through CRISPR-mediated gene insertion [5] Financial Performance - The company reported a net loss of $147 million for Q2 2024, compared to a loss of $124 million in Q2 2023, with total operating expenses slightly increasing year-over-year [9][16] - Collaboration revenue decreased to $7 million in Q2 2024 from $13.6 million in the same quarter of 2023, primarily due to reduced revenue from the AvenCell collaboration [9][16] Corporate Updates - Intellia appointed Brian Goff to its board of directors and Edward Dulac as Chief Financial Officer, enhancing its leadership team [8]

Phase 2 study of NTLA-2002 for hereditary angioedema (HAE) met its primary and all secondary endpoints; plan to present detailed results at an upcoming medical meeting in the fourth quarter Selected the 50 mg dose of NTLA-2002 for the pivotal Phase 3 trial on track to begin in 2H 2024 Rapid enrollment continues in the Phase 3 MAGNITUDE trial of NTLA-2001 for the treatment of transthyretin (ATTR) amyloidosis with cardiomyopathy On track to initiate the Phase 3 study of NTLA-2001 for the treatment of heredita ...

As a rule of thumb, you want to make market decisions based on a wide range of assessments and not just on the recommendation of a popular investor. That said, if you had to trade with a particular individual, you can do a lot worse than so-called Cathie Wood stocks. An entrepreneur and a tech visionary, Wood is considered a star stock picker. She's the founder of ARK Invest, which features around $60 billion worth of assets. Part of the reason for considering the ideas she supports is longevity. Wood has b ...

CAMBRIDGE, Mass., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, will present its second quarter 2024 financial results and operational highlights in a conference call on August 8, 2024, at 8 a.m. ET. To join the call: U.S. callers should dial 1-833-316-0545 and international callers should dial 1-412-317-5726, approximately five minutes before the call. All participan ...

CAMBRIDGE, Mass., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, will present its second quarter 2024 financial results and operational highlights in a conference call on August 8, 2024, at 8 a.m. ET. To join the call: U.S. callers should dial 1-833-316-0545 and international callers should dial 1-412-317-5726, approximately five minutes before the call. All participan ...

NTLA-3001 is a potential one-time gene editing treatment that may normalize AAT protein levels and halt the progression of lung disease associated with alpha-1 antitrypsin deficiency (AATD) NTLA-3001 is Intellia's first wholly owned CRISPR-based in vivo targeted gene insertion candidate to advance into the clinic On track to dose the first patient in 2H 2024 CAMBRIDGE, Mass., July 30, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on ...

NTLA-3001 is a potential one-time gene editing treatment that may normalize AAT protein levels and halt the progression of lung disease associated with alpha-1 antitrypsin deficiency (AATD) NTLA-3001 is Intellia's first wholly owned CRISPR-based in vivo targeted gene insertion candidate to advance into the clinic On track to dose the first patient in 2H 2024 "NTLA-3001 is a groundbreaking in vivo CRISPR-based gene insertion candidate designed to durably produce functional AAT protein at normal levels after ...

Core Viewpoint - Intellia Therapeutics, Inc. (NTLA) has been upgraded to a Zacks Rank 1 (Strong Buy), indicating a positive outlook based on rising earnings estimates, which are a significant factor influencing stock prices [1][4][11]. Earnings Estimates and Stock Movement - Changes in a company's future earnings potential, as indicated by earnings estimate revisions, are strongly correlated with near-term stock price movements [3][5]. - Institutional investors utilize earnings estimates to determine the fair value of a company's shares, leading to buying or selling actions that affect stock prices [3]. Intellia Therapeutics' Earnings Outlook - Intellia Therapeutics is projected to earn -$5.08 per share for the fiscal year ending December 2024, reflecting a year-over-year change of 6.3% [7]. - Over the past three months, the Zacks Consensus Estimate for Intellia has increased by 10.5%, indicating a positive trend in earnings estimates [7]. Zacks Rank System - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with Zacks Rank 1 stocks historically generating an average annual return of +25% since 1988 [6][12]. - The upgrade of Intellia Therapeutics to Zacks Rank 1 places it in the top 5% of Zacks-covered stocks, suggesting potential for stock price appreciation in the near term [9][12].

Let's get down to it: why should investors consider pharma stocks? Primarily, it comes down to the permanence of the underlying narrative. So long as humans are afflicted by various diseases, there will be a need for advanced pharmaceutical solutions. Therefore, money has been flowing into the broader biotechnology space and that will probably not fade anytime soon. Plus, as an American investor, you're in luck. Just the U.S. sector itself reached a valuation of $246.18 billion last year. By 2033, the domes ...